Lumida
/UTMD
⌘K
Utah Medical Products Inc

Utah Medical Products Inc

UTMD
$69.71USD↑+0.10%+0.07 today

MARKET CAP

221.9M

P/E (TTM)

20.6x

FWD P/E

—

DAY RANGE

$69 – $70

52W RANGE

$54
$76

AI Summary

Stalk
Sell NowHigh

UTMD’s price has dipped below the 9EMA, 20EMA, and 50DMA with an active Lower Highs & Lower Lows pattern indicating supply dominance and downward momentum. In a Stage 4 decline with neutral OB/OS, the medium-term posture remains bearish. Short-term timing conditions align with further downside as price tightly tracks below sloping EMAs. Execution is now appropriate on rallies into the broken EMA cluster. Only a sustained reclaim above these EMAs and recent resistance zone would invalidate this stance.

  • ↑Earnings Yield 36.7% and Dividend Yield 1.8% support income investors.
  • ↑Q2 revenue fell 14.3% to $8.53M while gross margin stayed 55.8%.
  • ↓2026 sales forecast cut 10–13% after customer losses
Full analysis →

Buying

3

institutions

Selling

3

institutions

New Positions

0

this quarter

Filing Period

Q2 2026

latest 13-F

13-F Holdings

Institution↕Action↕Shares Held↕Value↓Change↕Chg %↕Weight↕
BI

Blackrock, Inc.

Q2 2026

BUY203.69 K14.05 M+16.04 K+20.8%0.00%
RT

Renaissance Technologies LLC

Q2 2026

SELL175.81 K12.13 M+-8.30 K+6.3%0.02%
AC

Aqr Capital Management LLC

Q2 2026

BUY14.99 K1.03 M+4.72 K+62.4%0.00%
JC

Jpmorgan Chase & Co

Q2 2026

BUY1.63 K119.18 K+101.00+20.2%0.00%
MM

Millennium Management LLC

Q2 2026

SELL0.000.00+-6.77 K-100.0%0.00%
RC

Rockefeller Capital Management L.P.

Q2 2026

SELL0.000.00+-273.00-100.0%0.00%